GlassScriptPhysician profile
Joshua A Davis
NPI 1316018641
$18,693.36
in general payments reported to CMS, 2019-2025
56 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,951 · 2020: $1,359 · 2021: $1,062 · 2022: $1,460 · 2023: $1,928 · 2024: $2,757 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,842 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,841.75 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $5,819.69 | 2019 | |
| Novo Nordisk INC | $2,224.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,530.10 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,488.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,260.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,102.76 | 2019-2025 | |
| Amgen INC. | $1,043.30 | 2019-2025 | Evenity, Repatha, Prolia |
| Glaxosmithkline, LLC. | $450.04 | 2019-2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $329.24 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $325.31 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.90 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $182.05 | 2019-2023 | |
| Abbott Laboratories | $158.09 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $157.20 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $155.39 | 2019-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.